FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Brian Feagan

Research Profile

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Co-author Network

Publications

TOP 3
Krisztina B Gecse; Vipul Jairath; Reena Khanna; Mark Löwenberg; Cyriel Y Ponsioen; William J Sandborn; Simon P L Travis; Gijs R van den Brink; Brian G Feagan; Geert D'Haens
Biosimilars in IBD: hope or expectation?
Mahmoud H Mosli; Brian G Feagan
Vedolizumab for Crohn's disease.
Reena Khanna; Brian G Feagan
Through the looking glass: a journey toward optimal endoscopic assessment of disease activity in ulcerative colitis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Brian Feagan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Krisztina B Gecse; Vipul Jairath; Reena Khanna; Mark Löwenberg; Cyriel Y Ponsioen; William J Sandborn; Simon P L Travis; Gijs R van den Brink; Brian G Feagan; Geert D'Haens
Biosimilars in IBD: hope or expectation?
Gut 2013;62(6):803-7.
2013: Mahmoud H Mosli; Brian G Feagan
Vedolizumab for Crohn's disease.
Expert opinion on biological therapy 2013;13(3):455-63.
2013: Reena Khanna; Brian G Feagan
Through the looking glass: a journey toward optimal endoscopic assessment of disease activity in ulcerative colitis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2013;11(1):55-6.
2012: Wolfgang Hueber; Jacek Karczewski; Marek Karczewski; Steve Lewitzky; Marco Londei; Bjoern Mellgard; Nicole Pezous; Walter Reinisch; Bruce E Sands; Gervais Tougas; Simon P L Travis; Marc Vandemeulebroecke; Jan Wehkamp; Michael D Yao; Stephan Bek; Claudia Berger; Arthur P Bertolino; Gerard Bruin; Brian G Feagan; Peter Higgins
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Gut 2012;61(12):1693-700.
2012: Jonathan Kay; Edward C Keystone; Agnes V Klein; Anthony S Lubiniecki; Diane R Mould; Kwasi A Nyarko; Anthony A G Ridgway; Maureen E Trudeau; Brian G Feagan; Micheal S Guirguis; Jian Wang
Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012.
Biologicals : journal of the International Association of Biological Standardization 2012;40(6):517-27.
2012: Ingrid Ordás; Brian G Feagan; William J Sandborn
Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2012;10(10):1079-87; quiz e85-6.
2012: Gary R Lichtenstein; Anil Londhe; Samiyeh Price; Bruce A Salzberg; Russell D Cohen; Robert H Diamond; Brian G Feagan; Wayne Langholff; William J Sandborn
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
The American journal of gastroenterology 2012;107(9):1409-22.
2012: Brian G Feagan; John K Macdonald
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis.
Inflammatory bowel diseases 2012;18(9):1785-94.
2012: Asit Parikh; Terry Ponich; Serap Sankoh; Catherine Scholz; Tim Wyant; Irving Fox; Timothy Leach; Diane R Mould; Brian G Feagan
Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.
Inflammatory bowel diseases 2012;18(8):1470-9.
2012: S P L Travis; Bruce R Yacyshyn; Bruce E Sands; Dan Schnell; Maria Abreu; Douglas G Altman; Christian A Bernhardt; Jean-Frédéric Colombel; Brian G Feagan; Stephen B Hanauer; Piotr Krzeski; Marc Lémann; Gary R Lichtenstein; Phillippe R Marteau; Jean-Yves Mary; Walter Reinisch; William J Sandborn
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
Gut 2012;61(4):535-42.
2012: Simon Travis; Brian G Feagan; Paul Rutgeerts; Sander van Deventer
The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy.
Journal of Crohn's & colitis 2012;6 Suppl 2():S250-9.
2012: Subrata Ghosh; Mark S Silverberg; Geert D'Haens; Brian G Feagan; Eva M Szigethy
What do changes in inflammatory bowel disease management mean for our patients?
Journal of Crohn's & colitis 2012;6 Suppl 2():S243-9.
2012: Alain Bitton; Donald Buie; Robert Enns; Brian G Feagan; Anne M Griffiths; Jennifer L Jones; John K Marshall; Remo Panaccione; Scott Whittaker
Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements.
The American journal of gastroenterology 2012;107(2):179-94; author reply 195.
2012: John W D McDonald; David J Tsoulis; John K Macdonald; Brian G Feagan
Methotrexate for induction of remission in refractory Crohn's disease.
Cochrane database of systematic reviews (Online) 2012;12():CD003459.
2012: Brian G Feagan; John K Macdonald
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Cochrane database of systematic reviews (Online) 2012;10():CD000544.
2012: Brian G Feagan; John K Macdonald
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Cochrane database of systematic reviews (Online) 2012;10():CD000543.
2011: Ingrid Ordás; Brian G Feagan; William J Sandborn
Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change.
Gut 2011;60(12):1754-63.
2011: Jean-Frédéric Colombel; Dirk Esser; Brian G Feagan; Stephen B Hanauer; Yinghua Lang; Gary R Lichtenstein; Colleen W Marano; Björn J Oddens; Daniel Present; Walter Reinisch; Paul Rutgeerts; Bruce E Sands; Richard Strauss; Yanxin Wang; William J Sandborn
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Gastroenterology 2011;141(4):1194-201.
2011: William J Sandborn; Stefan Schreiber; Ziad H Younes; Ralph Bloomfield; Geoffroy Coteur; Brian G Feagan; Juan Pablo Guzman; Paul Rutgeerts; Geert R D'Haens
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011;9(8):670-678.e3.
2011: Brian G Feagan; Stephen B Hanauer; G Coteur; S Schreiber
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.
Alimentary pharmacology & therapeutics 2011;33(10):1143-51.
2011: Brian G Feagan; William J Sandborn; D C Wolf; Geoffroy Coteur; O Purcaru; Y Brabant; Paul Rutgeerts
Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
Alimentary pharmacology & therapeutics 2011;33(5):541-50.
2011: Sigrid A E Nelson; George K Dresser; Margaret K Vandervoort; Cindy J Wong; Brian G Feagan; Jeffrey L Mahon; Ross D Feldman
Barriers to blood pressure control: a STITCH substudy.
Journal of clinical hypertension (Greenwich, Conn.) 2011;13(2):73-80.
2011: Brian G Feagan; John W McDonald; Nilesh Chande; John K MacDonald
Introduction to Cochrane systematic reviews.
Inflammatory bowel diseases 2011;17(1):334-5.
2010: Brian G Feagan; Asit Parikh
Response to Baumgart review.
Inflammatory bowel diseases 2010;16(9):1449.
2010: Brian G Feagan; M C Reilly; L Gerlier; Y Brabant; M Brown; Stefan Schreiber
Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
Alimentary pharmacology & therapeutics 2010;31(12):1276-85.
2009: William J Sandborn; Jaroslaw Regula; Brian G Feagan; Elena Belousova; Njegica Jojic; Milan Lukas; Bruce Yacyshyn; Piotr Krzeski; Chyon-Hwa Yeh; Christi A Messer; Stephen B Hanauer
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Gastroenterology 2009;137(6):1934-43.e1-3.
2009: Geert R D'Haens; Richard Fedorak; Marc Lémann; Brian G Feagan; Michael A Kamm; Jacques Cosnes; Paul J Rutgeerts; Philippe Marteau; Simon Travis; Jürgen Schölmerich; Steven Hanauer; William J Sandborn
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
Inflammatory bowel diseases 2009;15(10):1599-604.
2009: William J Sandborn; Paul Rutgeerts; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Jiandong Lu; Kevin Horgan; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel H Present; Bruce Sands; Jean-Frédéric Colombel
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
Gastroenterology 2009;137(4):1250-60; quiz 1520.
2009: Brian G Feagan; Geoffroy Coteur; Seng Tan; Dorothy L Keininger; Stefan Schreiber
Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.
The American journal of gastroenterology 2009;104(8):1976-83.
2009: Ross D Feldman; Guang Y Zou; Margaret K Vandervoort; Cindy J Wong; Sigrid A E Nelson; Brian G Feagan
A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.
Hypertension 2009;53(4):646-53.
2008: Brian G Feagan; Remo Panaccione; William J Sandborn; Geert D'Haens; Stefan Schreiber; Paul J Rutgeerts; Edward V Loftus; Kathleen G Lomax; Andrew P Yu; Eric Q Wu; Jingdong Chao; Parvez Mulani
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
Gastroenterology 2008;135(5):1493-9.
2008: Jennifer Jones; Edward V Loftus; Remo Panaccione; Li-Sheng Chen; Sandra Peterson; Joseph McConnell; Linnea Baudhuin; Karen Hanson; Brian G Feagan; Scott W Harmsen; Alan R Zinsmeister; Emelie Helou; William J Sandborn
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2008;6(11):1218-24.
2008: William J Sandborn; Brian G Feagan; Richard N Fedorak; Ellen Scherl; Mark R Fleisher; Seymour Katz; Jewel Johanns; Marion Blank; Paul Rutgeerts
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Gastroenterology 2008;135(4):1130-41.
2008: Remo Panaccione; P Rutgeerts; William J Sandborn; Brian G Feagan; Stefan Schreiber; S Ghosh
Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.
Alimentary pharmacology & therapeutics 2008;28(6):674-88.
2008: Alexandra Kirkley; Trevor B Birmingham; Robert B Litchfield; J Robert Giffin; Kevin R Willits; Cindy J Wong; Brian G Feagan; Allan Donner; Sharon H Griffin; Linda M D'Ascanio; Janet E Pope; Peter J Fowler
A randomized trial of arthroscopic surgery for osteoarthritis of the knee.
The New England journal of medicine 2008;359(11):1097-107.
2008: Brian G Feagan; William J Sandborn; Ulrich Mittmann; Simon Bar-Meir; Geert D'Haens; Marc Bradette; Albert Cohen; Chrystian Dallaire; Terry P Ponich; J W D McDonald; Xavier Hébuterne; Pierre Paré; Pavel Klvana; Yaron Niv; Sandro Ardizzone; Olga Alexeeva; Alaa Rostom; Gediminas Kiudelis; Johannes Spleiss; Denise Gilgen; Margaret K Vandervoort; Cindy J Wong; Guang Yong Zou; Allan Donner; Paul Rutgeerts
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials.
JAMA : the journal of the American Medical Association 2008;299(14):1690-7.
2008: Remo Panaccione; Richard N Fedorak; Guy Aumais; Edmond-Jean Bernard; C N Bernstein; Alain Bitton; Ken Croitoru; Levinus A Dieleman; Robert Enns; Brian G Feagan; D Franchimont; Gordon R Greenberg; Anne M Griffiths; John K Marshall; P Pare; S Patel; R Penner; C Render; Ernest Seidman; A Hillary Steinhart
Review and clinical perspectives for the use of infliximab in ulcerative colitis.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2008;22(3):261-72.
2008: Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van de Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Lancet 2008;371(9613):660-7.
2008: Daniel Baumgart; John K Macdonald; Brian G Feagan
Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis.
Cochrane database of systematic reviews (Online) 2008;(3):CD007216.
2007: Brian G Feagan; William J Sandborn; Steven Hass; Timothy Niecko; Jeffrey White
Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.
The American journal of gastroenterology 2007;102(12):2737-46.
2007: William J Sandborn; Brian G Feagan; Gary R Lichtenstein
Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
Alimentary pharmacology & therapeutics 2007;26(7):987-1003.
2007: Walter Reinisch; William J Sandborn; Mohan Bala; Songkai Yan; Brian G Feagan; Paul Rutgeerts; Graham Radford-Smith; Stephen Xu; Debra Eisenberg; Allan Olson; Jean-Frédéric Colombel
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis.
Inflammatory bowel diseases 2007;13(9):1135-40.
2007: William J Sandborn; Brian G Feagan; Simeon Stoinov; Pieter J Honiball; Paul Rutgeerts; David Mason; Ralph Bloomfield; Stefan Schreiber
Certolizumab pegol for the treatment of Crohn's disease.
The New England journal of medicine 2007;357(3):228-38.
2007: Martin Buxton; Loretto A Lacey; Brian G Feagan; Timothy Niecko; David W Miller; Raymond J Townsend
Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index in Crohn's disease and measures of utility.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2007;10(3):214-20.
2007: Stephan R Targan; Brian G Feagan; Richard N Fedorak; Bret A Lashner; Remo Panaccione; Daniel H Present; Martina E Spehlmann; Paul J Rutgeerts; Zsolt Tulassay; Miroslava Volfova; Douglas C Wolf; Chito Hernandez; Jeffrey Bornstein; William J Sandborn
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Gastroenterology 2007;132(5):1672-83.
2007: Cindy J Wong; Margaret K Vandervoort; Suzanne L Vandervoort; Allan Donner; Guangyong Zou; John K Macdonald; John Freedman; Keyvan Karkouti; Steven J Macdonald; Brian G Feagan
A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty.
Transfusion 2007;47(5):832-41.
2007: Brian G Feagan; Walter Reinisch; Paul Rutgeerts; William J Sandborn; Songkai Yan; Debra Eisenberg; Mohan Bala; Jewel Johanns; Allan Olson; Stephen B Hanauer
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
The American journal of gastroenterology 2007;102(4):794-802.
2007: Geert D'Haens; William J Sandborn; Brian G Feagan; Karel Geboes; Stephen B Hanauer; E Jan Irvine; Marc Lémann; Philippe Marteau; Paul Rutgeerts; Jurgen Schölmerich; Lloyd R Sutherland
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
Gastroenterology 2007;132(2):763-86.
2006: Gert van Assche; William J Sandborn; Brian G Feagan; Bruce A Salzberg; D Silvers; P S Monroe; W M Pandak; F H Anderson; John Valentine; G E Wild; D J Geenen; R Sprague; S R Targan; Paul Rutgeerts; V Vexler; D Young; R S Shames
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Gut 2006;55(11):1568-74.
2006: Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Donny M Chen; Michelle L Pritchard; William J Sandborn
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006;4(5):621-30.
2006: Gary R Lichtenstein; Allan Olson; Suzanne Travers; Robert H Diamond; Donny M Chen; Michelle L Pritchard; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Stephen B Hanauer; William J Sandborn
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
The American journal of gastroenterology 2006;101(5):1030-8.
2006: Stefan Schreiber; Brian G Feagan; Geert D'Haens; Jean-Frédéric Colombel; Karel Geboes; Mikhail Yurcov; Vasily Isakov; Oleg Golovenko; Charles N Bernstein; Diether Ludwig; Trevor Winter; Ulrich Meier; Chan Yong; Jürgen Steffgen
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006;4(3):325-34.
2006: Brian G Feagan; William J Sandborn; Gary R Lichtenstein; Graham Radford-Smith; J Patel; A Innes
CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Alimentary pharmacology & therapeutics 2006;23(5):617-28.
2005: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel H Present; Bruce Sands; Jean-Frédéric Colombel
Infliximab for induction and maintenance therapy for ulcerative colitis.
The New England journal of medicine 2005;353(23):2462-76.
2005: William J Sandborn; Jean-Frédéric Colombel; Roberts Enns; Brian G Feagan; Stephen B Hanauer; Ian Craig Lawrance; Remo Panaccione; Martin Sanders; Stefan Schreiber; Stephan R Targan; Sander J H van Deventer; Ronald Goldblum; Darrin Despain; Gary S Hogge; Paul Rutgeerts
Natalizumab induction and maintenance therapy for Crohn's disease.
The New England journal of medicine 2005;353(18):1912-25.
2005: William J Sandborn; Robert Löfberg; Brian G Feagan; Stephen B Hanauer; Massimo Campieri; Gordon R Greenberg
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
The American journal of gastroenterology 2005;100(8):1780-7.
2005: Brian G Feagan; Gordon R Greenberg; Gary Wild; Richard N Fedorak; Pierre Paré; J W D McDonald; Rejean Dubé; Albert Cohen; A Hillary Steinhart; Steven Landau; Rasha A Aguzzi; Irving H Fox; Margaret K Vandervoort
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
The New England journal of medicine 2005;352(24):2499-507.
2005: Brian G Feagan; Mohan Bala; Songkai Yan; Allan Olson; Stephen B Hanauer
Unemployment and disability in patients with moderately to severely active Crohn's disease.
Journal of clinical gastroenterology 2005;39(5):390-5.
2005: Brian G Feagan; William J Sandborn; J P Baker; F Cominelli; L R Sutherland; C O Elson; Bruce A Salzberg; A Archambault; C N Bernstein; Gary R Lichtenstein; P K Heath; S Cameron; Stephen B Hanauer
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Alimentary pharmacology & therapeutics 2005;21(4):373-84.
2005: Anne M Griffiths; Anthony Otley; Jeffrey Hyams; Antonio R Quiros; Richard J Grand; Athos Bousvaros; Brian G Feagan; George R Ferry
A review of activity indices and end points for clinical trials in children with Crohn's disease.
Inflammatory bowel diseases 2005;11(2):185-96.
2005: J W D McDonald; Brian G Feagan; D Jewell; J Brynskov; E F Stange; John K Macdonald
Cyclosporine for induction of remission in Crohn's disease.
Cochrane database of systematic reviews (Online) 2005;(2):CD000297.
2004: Brian G Feagan
Endoscopic scoring system for Crohn's disease: viva the evolution!
Gastrointestinal endoscopy 2004;60(4):590-1.
2004: William J Sandborn; Brian G Feagan; Graham Radford-Smith; A Kovacs; R Enns; A Innes; J Patel
CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
Gut 2004;53(10):1485-93.
2004: William J Sandborn; Brian G Feagan
The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain.
Gastroenterology 2004;127(3):990-3.
2004: William S Mow; Carol J Landers; A Hillary Steinhart; Brian G Feagan; Ken Croitoru; Ernest Seidman; Gordon R Greenberg; Stephan R Targan
High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study.
Digestive diseases and sciences 2004;49(7-8):1280-6.
2004: Remo Panaccione; Richard N Fedorak; Guy Aumais; Charles N Bernstein; Alain Bitton; Ken Croitoru; Robert Enns; Brian G Feagan; Marty Fishman; Gordon Greenberg; Anne Griffiths; John K Marshall; Imran Rasul; Daniel C Sadowski; Ernest Seidman; Hillary Steinhart; Lloyd Sutherland; Eric Walli; Gary Wild; C Noel Williams; Mary Zachos
Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2004;18(8):503-8.
2004: Brian G Feagan; Ahmad Alfadhli
Methotrexate in inflammatory bowel disease.
Gastroenterology clinics of North America 2004;33(2):407-20, xi.
2004: Brian G Feagan
5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2004;2(5):376-8.
2004: Bruce Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne Travers; Marion A Blank; Sander J H van Deventer
Infliximab maintenance therapy for fistulizing Crohn's disease.
The New England journal of medicine 2004;350(9):876-85.
2004: Paul Rutgeerts; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; Stefan Schreiber; Jean-Frédéric Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Stephen B Hanauer
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
Gastroenterology 2004;126(2):402-13.
2003: Brian G Feagan
Maintenance therapy for inflammatory bowel disease.
The American journal of gastroenterology 2003;98(12 Suppl):S6-S17.
2003: William J Sandborn; Victor W Fazio; Brian G Feagan; Stephen B Hanauer
AGA technical review on perianal Crohn's disease.
Gastroenterology 2003;125(5):1508-30.
2003: Brian G Feagan; Songkai Yan; Mohan Bala; Weihang Bao; Gary R Lichtenstein
The effects of infliximab maintenance therapy on health-related quality of life.
The American journal of gastroenterology 2003;98(10):2232-8.
2003: William J Sandborn; Brian G Feagan
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
Alimentary pharmacology & therapeutics 2003;18(3):263-77.
2003: William J Sandborn; Daniel H Present; Kim L Isaacs; Douglas C Wolf; Eugene Greenberg; Stephen B Hanauer; Brian G Feagan; Lloyd Mayer; Therese Johnson; Joseph A Galanko; Christopher F Martin; Robert S Sandler
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.
Gastroenterology 2003;125(2):380-8.
2002: Brian G Feagan; David B Sachar
What do I do in my practice that isn't evidence based?
Inflammatory bowel diseases 2002;8(6):422-5; discussion 426-7.
2002: Brian G Feagan
Review: one tenth of patients with Crohn disease have prolonged remission.
ACP journal club 2002;137(3):115.
2002: Brian G Feagan
The efficacy, safety and acceptance of autologous blood donation as a blood conservation strategy.
Vox sanguinis 2002;83 Suppl 1():11-2.
2002: Sunanda V Kane; Philip Schoenfeld; William J Sandborn; W Tremaine; Timothy P Hofer; Brian G Feagan
The effectiveness of budesonide therapy for Crohn's disease.
Alimentary pharmacology & therapeutics 2002;16(8):1509-17.
2002: A Hillary Steinhart; Brian G Feagan; Cindy J Wong; Margaret K Vandervoort; Shelley Mikolainis; Ken Croitoru; Ernest Seidman; Desmond J Leddin; Alain Bitton; Eric Drouin; Albert Cohen; Gordon R Greenberg
Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial.
Gastroenterology 2002;123(1):33-40.
2002: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean-Frédéric Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Lancet 2002;359(9317):1541-9.
2002: Brian G Feagan; Cindy J Wong; William C Johnston; Ramiro Arellano; Nigel Colterjohn; Keyvan Karkouti; Kim Turner
Transfusion practices for elective orthopedic surgery.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2002;166(3):310-4.
2002: William J Sandborn; Brian G Feagan; Stephen B Hanauer; Herbert Lochs; Robert Löfberg; Robert Modigliani; Daniel H Present; Paul Rutgeerts; Jurgen Schölmerich; Eduard F Stange; Lloyd R Sutherland
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.
Gastroenterology 2002;122(2):512-30.
2002: Brian G Feagan; William J Sandborn
Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Reviews in gastroenterological disorders 2002;2 Suppl 2():S9-15.
2002: J W D McDonald; Jeffrey L Mahon; Kelly B Zarnke; Brian G Feagan; Lorinda Simms; Wayne Tucker
A randomized survey of the preference of gastroenterologists for a Cochrane review versus a traditional narrative review.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2002;16(1):17-21.
2001: Brian G Feagan
A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Pharmacotherapy 2001;21(7 Pt 2):89S-94S.
2001: William J Sandborn; Brian G Feagan; Stephen B Hanauer; Daniel H Present; L R Sutherland; M A Kamm; D C Wolf; J P Baker; C Hawkey; A Archambault; C N Bernstein; C Novak; P K Heath; S R Targan
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
Gastroenterology 2001;120(6):1330-8.
2001: Brian G Feagan
Safety of biologics: current issues and future concerns.
Acta gastro-enterologica Belgica 2001;64(2):210-4.
2001: Brian G Feagan
Standard immunosuppression in IBD: current practice.
Acta gastro-enterologica Belgica 2001;64(2):182-8.
2001: Brian G Feagan; Cindy J Wong; CY Lau; SL Wheeler; G Sue-A-Quan; A Kirkley
Transfusion practice in elective orthopaedic surgery.
Transfusion medicine (Oxford, England) 2001;11(2):87-95.
2001: Brian G Feagan; R Enns; Richard N Fedorak; Remo Panaccione; P Paré; A Hillary Steinhart; Gary Wild
Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 2001;8(4):188-98.
2000: Brian G Feagan; Cindy J Wong; A Kirkley; D W Johnston; F C Smith; P Whitsitt; SL Wheeler; CY Lau
Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial.
Annals of internal medicine 2000;133(11):845-54.
2000: Richard N Fedorak; A Gangl; Charles O Elson; Paul Rutgeerts; S Schreiber; Gary Wild; Stephen B Hanauer; A Kilian; M Cohard; LeBeaut Pierre Alexandre; Brian G Feagan
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
Gastroenterology 2000;119(6):1473-82.
2000: Thomas J Marrie; CY Lau; SL Wheeler; C J Wong; Brian G Feagan
Predictors of symptom resolution in patients with community-acquired pneumonia.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31(6):1362-7.
2000: E Jan Irvine; Gordon R Greenberg; Brian G Feagan; F Martin; L R Sutherland; Alan B R Thomson; L G Nilsson; T Persson
Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
Inflammatory bowel diseases 2000;6(3):181-7.
2000: Brian G Feagan; M G Vreeland; LR Larson; Mohan Bala
Annual cost of care for Crohn's disease: a payor perspective.
The American journal of gastroenterology 2000;95(8):1955-60.
2000: Brian G Feagan; Richard N Fedorak; E J Irvine; Gary Wild; Lloyd Sutherland; A Hillary Steinhart; Gordon R Greenberg; J Koval; C J Wong; M Hopkins; S B Hanauer; J W D McDonald
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
The New England journal of medicine 2000;342(22):1627-32.
2000: Brian G Feagan; Thomas J Marrie; CY Lau; SL Wheeler; Cindy J Wong; Margaret K Vandervoort
Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2000;162(10):1415-20.
2000: Thomas J Marrie; CY Lau; SL Wheeler; C J Wong; Margaret K Vandervoort; Brian G Feagan
A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
JAMA : the journal of the American Medical Association 2000;283(6):749-55.
1999: Brian G Feagan
Review article: economic issues in Crohn's disease--assessing the effects of new treatments on health-related quality of life.
Alimentary pharmacology & therapeutics 1999;13 Suppl 4():29-37; discussion 38.
1999: William J Sandborn; William J Tremaine; D C Wolf; Stephan R Targan; C A Sninsky; L R Sutherland; Stephen B Hanauer; J W McDonald; Brian G Feagan; Richard N Fedorak; Kim L Isaacs; MG Pike; Dennis C Mays; James J Lipsky; S Gordon; CS Kleoudis; RH Murdock
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
Gastroenterology 1999;117(3):527-35.
1998: Brian G Feagan
Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
The European journal of surgery = Acta chirurgica 1998;164(12):903-9.
1997: R Hamedani; R D Feldman; Brian G Feagan
Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapy.
Alimentary pharmacology & therapeutics 1997;11 Suppl 3():98-107; discussion 107-8.
1997: K A Atkinson; J W D McDonald; B Lamba; Brian G Feagan
Intravenous cyclosporine for severe attacks of ulcerative colitis: a survey of Canadian gastroenterologists.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie 1997;11(7):583-7.
1997: Brian G Feagan
Antibiotics are not effective therapy for Crohn's disease (time to remove the rose-coloured glasses).
Inflammatory bowel diseases 1997;3(4):314-7.
1997: J C Gregor; N Klar; B Lamba; J W McDonald; R Wall; K Atkinson; Brian G Feagan
An evaluation of utility measurement in Crohn's disease.
Inflammatory bowel diseases 1997;3(4):265-76.
1997: Brian G Feagan
Methotrexate for ulcerative colitis-discouraging news.
Inflammatory bowel diseases 1997;3(2):178-9.
1996: LE Probst; E Hoffman; M G Cherian; J Yang; Brian G Feagan; P Adams; B Nichols
Ocular copper deposition associated with benign monoclonal gammopathy and hypercupremia.
Cornea 1996;15(1):94-8.
1996: Brian G Feagan; J W McDonald; J J Koval
Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trials.
Gastroenterology 1996;110(1):275-83.
1995: Jeffrey L Mahon; Brian G Feagan; A Laupacis
Ethics of n-of-1 trials.
Lancet 1995;345(8955):989.
1991: Jeffrey L Mahon; K Steel; Brian G Feagan; A Laupacis; L L Pederson
Use of acetylsalicylic acid by physicians and in the community.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 1991;145(9):1107-16.